global messaging alerts

ApiJect Announces Roseanne Hofmann, PhD, MBA as New Chief Pharmaceutical Sciences Officer

Stamford, CT, May 17, 2022  –ApiJect Systems, Inc., a medical technology company that seeks to revolutionize how medicines and vaccines are filled, finished, and delivered, announced today the hiring of Roseanne Hofmann, PhD, MBA as ApiJect’s Chief Pharmaceutical Sciences Officer.

Dr. Hofmann is an accomplished global business leader and scientist. She has led global teams overseeing biologicals, vaccines, and generic injectable products, accomplishing transformational growth initiatives through creative solutions.

Dr. Hofmann has a distinguished career in the pharmaceutical industry which includes time as a scientist, leader of functions and senior leader of multinational companies. She served most recently as Vice President of Digitalization Excellence and Strategy, at Bristol-Myers Squibb where she led supply chain digitization and other global product development and supply efforts. Previously, Dr. Hofmann served as the Master Architect of Manufacturing Systems Design and Commercialization for Merck, implementing biologics and vaccine manufacturing best practices in new manufacturing infrastructure investments. She has held numerous other leadership roles in manufacturing, manufacturing sciences, quality, strategy, global expansion and business brand leadership at Abcam, Pfizer Inc. and Novartis Vaccines & Diagnostics.

Dr. Hofmann holds a BA in Chemistry and Mathematics from La Salle University, an MBA from Saint Joseph’s University, and a PhD in Biochemistry & Molecular Biology from Johns Hopkins University. She completed a Post-Doctoral program at The Rockefeller University and was an Adjunct Professor in Biotechnology at Johns Hopkins University.

Dr. Hofmann commented: “I am excited to be joining the team to scale the ApiJect platform to our partners, serving the globe with innovative solutions for the delivery of sterile injectable products.” 

Jay Walker, ApiJect CEO, stated: “In Dr. Hofmann we have the right person arriving at the right time for this new role as Chief Pharmaceutical Officer at ApiJect.  Dr. Hofmann will lead ApiJect in the critical areas of new product introductions and existing product development, as well as leading the company’s cross functional teams. In this position, Dr. Hofmann will work with device engineers, senior leaders, external partners, and regulatory stakeholders, as well as quality teams.”

Mr. Walker continued: “Dr. Hofmann is uniquely qualified to lead many of ApiJect’s diverse but interconnected functions, having spent significant time in operations and technical leadership, quality and regulatory, productivity, and process and design leadership. She brings to ApiJect a track record of success in numerous global growth and improvement efforts.  Her time as an adjunct professor at Johns Hopkins, numerous trainings, and “digital boot camps” demonstrate the value she places on learning and the development of teams. I speak for the entire ApiJect family, when I say how pleased we are with her decision to join our team.”

ApiJect Systems, Corp. is a public-benefit medical technology company working to bring prefilled, single-dose injections to more people in every market. The ApiJect Platform enables pharmaceutical and biotech companies to design scalable prefilled injectors and efficiently fill-finish them with their injectable drug products. This can be done either on one of their own ApiJect-licensed Blow-Fill-Seal packaging lines or at one of our world-class manufacturing partners.

Contact Steve Hofman at

random footer image
Social media & sharing icons powered by UltimatelySocial